ARSA and metachromatic leukodystrophy: In conclusion, with up to 7·5 years of follow-up, these data confirm that arsa-cel provides meaningful clinical benefit to patients with early-onset MLD treated in pre-symptomatic and early-symptomatic stages of the disease, validating it as an effective therapeutic approach to alleviate the severe burden of MLD.34